Showing results (41-50 of 77) with videos related to
Sort By:
Pageof 8
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.Blood Neoplasia|June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experienceMalin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.Blood Cancer Journal|May 27, 2024
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myelomaBruno Almeida Costa, Jessica Flynn, Noriko Nishimura, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson, Wanling Xie, Constantine Mitsiades, et al.Blood Advances|April 15, 2024
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapiesAnna J Howard, Isabel Concepcion, Alice X Wang, et al.Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.Pageof 8